Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity

Transfusion

Volumn 41, Issue 3, 2001, Pages 406-415

  Vamvakas, Eleftherios C ^a,b,c,d   Strauss, Ronald G ^a,b,c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HUMAN; META ANALYSIS; NEWBORN; NEWBORN PERIOD; OUTCOMES RESEARCH; PREMATURITY; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; BLOOD TRANSFUSION; CONTROLLED CLINICAL TRIALS; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; ODDS RATIO; RECOMBINANT PROTEINS;

EID: 0035077804     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41030406.x     Document Type: Article

References (58)

1. Erythropoietin in mRNA expression in human fetal and neonatal tissue
2. Erythropoietin pharmacokinetics in premature infants: Developmental, nonlineárity, and treatment effects
3. Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity
4. Postnatal changes in erythropoietin levels in untransfused premature infants
5. Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity
6. Enhancement of erythropoiesis by recombinant human erythropoietin in low-birth-weight infants: A pilot study
7. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants
8. Double blind trial of recombinant human erythropoietin in preterm infants
9. Erythropoietin, protein, and iron supplementation and the prevention of anemia of prematurity
10. Early treatment of premature infants with recombinant human erythropoietin
11. Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study
12. Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anemia of prematurity
13. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very-low-birth-weight preterm infants
14. Efficacy and cost analysis of treating very-low-birth-weight infants with erythropoietin during the first two weeks of life: A randomized, placebo-controlled trial
15. Recombinant human erythropoietin in the treatment of anemia of prematurity
16. Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anemia of prematurity
17. Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions
18. Effects of recombinant human erythropoietin in infants with very low birth weights
19. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: A randomized, double-blind, placebo-controlled study
20. Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very-low-birth-weight infants: A randomized, double-blind, placebo-controlled trial
21. Efficacy and safety of recombinant human erythropoietin to prevent the anemias of prematurity: European multicenter randomized trial
22. Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study
23. In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study
24. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group
25. Erythropoietin (Epo), protein and iron supplementation and the prevention of anemia of prematurity: Effects on serum immunoreactive Epo, growth and protein and iron metabolism
26. Randomized controlled double-blind study of role of recombinant erythropoietin in the prevention of chronic lung disease
27. Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia
28. Recombinant erythropoietin for the anemia of prematurity: Still a promise, not a panacea
29. Recombinant erythropoietin in the treatment of the premature newborn
30. Changing patterns of red blood cell transfusions in very low birth weight infants
31. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g
32. Erythropoietin--not yet a standard treatment for anemia of prematurity
33. Use of erythropoietin in premature neonates: Controversies and the future
34. The role of erythropoietin in the anemia of prematurity
35. Recombinant human erythropoietin in neonatal anemia
36. Erythropoietin and neonatal anemia
37. Erythropoietin in the pathogenesis and treatment of neonatal anemia
38. A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity
39. Effect of low and moderate doses of recombinant human erythropoietin on the hematological response in premature infants on a high protein and iron intake
40. High- versus low-dose erythropoietin in extremely low-birth-weight infants. The European Multicenter rHuEPO Study Group
41. Erythropoiesis of very low-birth-weight infants dependent on prenatal growth rate and protein status
42. Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: A randomized trial
43. Early rise in serum concentration of transferrin receptor induced by recombinant human erythropoietin in very-low-birth-weight infants
44. Increased hematocrit and decreased transfusion requirements in children given erythropoietin before undergoing craniofacial surgery
45. Erythropoietin, given enterally, stimulates erythropoiesis in premature infants
46. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants
47. Influence of recombinant human erythropoietin on neutrophil function in premature neonates
48. Oral iron is sufficient for erythropoietin treatment of very low birth-weight neonates
49. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants
50. A multicenter randomized double-masked placebo-controlled trial of early erythropoietin and iron administration to preterm infants
51. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
52. National acceptability of American Association of Blood Banks Pediatric Hemotherapy Committee guidelines for auditing pediatric transfusion practices
53. Meta-analysis in clinical trials
54. Beta blockade during and after myocardial infarction: An overview of the randomized trials
55. The combination of estimates from different experiments
56. Meta-analysis in transfusion medicine
57. Follow-up of very-low-birth-weight infants after erythropoietin treatment to prevent anemia of prematurity